Surmodics (NASDAQ:SRDX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Surmodics (NASDAQ:SRDX) in a report released on Monday morning. The brokerage issued a hold rating on the stock.

SRDX has been the subject of a number of other reports. Lake Street Capital reiterated a hold rating and set a $43.00 target price on shares of Surmodics in a report on Wednesday, May 29th. Needham & Company LLC reissued a hold rating on shares of Surmodics in a research note on Monday, August 5th. Barrington Research reissued a market perform rating on shares of Surmodics in a research note on Thursday, May 30th. Finally, Sidoti reiterated a neutral rating and issued a $43.00 price target on shares of Surmodics in a report on Wednesday, May 29th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Surmodics has an average rating of Hold and an average target price of $50.00.

Surmodics Stock Up 0.1 %

Shares of NASDAQ SRDX opened at $40.06 on Monday. The firm’s fifty day moving average is $41.53 and its 200 day moving average is $35.06. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44. The company has a quick ratio of 3.22, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. The company has a market cap of $571.66 million, a price-to-earnings ratio of 42.17 and a beta of 1.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SRDX. Hillsdale Investment Management Inc. boosted its position in shares of Surmodics by 15.7% during the fourth quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock valued at $166,000 after purchasing an additional 620 shares in the last quarter. Hardin Capital Partners LLC purchased a new position in Surmodics during the second quarter valued at $206,000. SG Americas Securities LLC boosted its holdings in shares of Surmodics by 14.7% during the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock valued at $151,000 after buying an additional 660 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Surmodics in the 2nd quarter worth about $229,000. Finally, Lazard Asset Management LLC increased its stake in shares of Surmodics by 13.4% in the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after acquiring an additional 673 shares in the last quarter. Hedge funds and other institutional investors own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).